The effectiveness of IL-1 blockade in treating many AIDs has also paved the way to targeting IL-1 in other non-hereditary conditions, such as systemic juvenile idiopathic arthritis, periodic fever/aphthosis/pharyngitis/adenitis syndrome and Kawasaki disease. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.